Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1080227 | 0.90 | CHRM1 (0.47) | PLA2G2AP2RX7HTR6LMNAMTNR1A | |
| SCHEMBL699995 | 0.84 | APP (0.50) | PLA2G2AAPPSNCACA12CA1 | |
| SCHEMBL31668287 | 0.82 | P2RX7 (0.47) | PLA2G2AAPPSNCACA12CA1 | |
| SCHEMBL703569 | 0.81 | NR4A2 (0.49) | L3MBTL1NR4A2ALDH1A1LMNA | |
| SCHEMBL13387413 | 0.80 | CHRM1 (0.45) | PLA2G2AP2RX7HTR6LMNAMTNR1A | |
| SCHEMBL702596 | 0.78 | MEN1 (0.58) | DRD2HTR6NR4A2LMNAHDAC10 | |
| SCHEMBL701364 | 0.76 | SLC16A3 (0.43) | L3MBTL1P2RX7ALDH1A1 | |
| SCHEMBL9484308 | 0.76 | MAPT (0.63) | APPSNCACA12CA1CA2 | |
| SCHEMBL9484312 | 0.76 | MAPT (0.63) | APPSNCACA12CA1CA2 | |
| SCHEMBL14784861 | 0.75 | PTGER1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710047-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| CN-102046176-B | 5-HT3Receptor modulators, methods of preparation and uses thereof | ALBANY MOLECULAR RES INC | 2013-08-07 | — | — | CN | disclosed |
| US-8501729-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8124600-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| CN-102046176-A | 5-HT3Receptor modulators, methods of preparation and uses thereof | ALBANY MOLECULAR RES INC | 2011-05-04 | — | — | CN | disclosed |
| EP-2310019-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009155054-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310366-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | PLA2G2A 1013/4885APP 4820/4885SNCA 4576/4885 |
| US-20090298809-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | PLA2G2A 1013/4885APP 4820/4885SNCA 4576/4885 |
| US-20120219641-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | PLA2G2A 1013/4885APP 4820/4885SNCA 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.